Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:FMTXNASDAQ:IMVTNASDAQ:KRYSNASDAQ:OCGNNASDAQ:RGNX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFMTXForma Therapeutics$20.01$20.00$4.95▼$20.68$957.54M-0.94847,595 shs1 shsIMVTImmunovant$32.52+3.5%$35.39$14.05▼$45.58$4.57B0.671.31 million shs932,768 shsKRYSKrystal Biotech$177.20+1.7%$140.68$77.10▼$189.97$4.93B0.86463,833 shs349,192 shsOCGNOcugen$1.78+2.9%$0.87$0.35▼$2.11$443.75M3.4410.83 million shs10.56 million shsRGNXREGENXBIO$22.18+2.4%$18.21$11.83▼$28.80$962.74M1.271.02 million shs561,385 shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFMTXForma Therapeutics0.00%0.00%0.00%0.00%0.00%IMVTImmunovant+3.47%+3.01%-14.76%-23.21%+109.81%KRYSKrystal Biotech+1.74%+3.43%+12.87%+38.70%+123.79%OCGNOcugen+2.89%+43.55%+97.78%+215.21%+114.46%RGNXREGENXBIO+2.35%-1.47%+20.94%+19.63%+17.79%Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFMTXForma TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AIMVTImmunovant2.5363 of 5 stars4.51.00.00.03.21.70.0KRYSKrystal Biotech3.862 of 5 stars1.53.00.04.72.03.31.9OCGNOcugen1.2089 of 5 stars3.52.00.00.03.10.00.0RGNXREGENXBIO4.662 of 5 stars4.41.00.04.62.53.30.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFMTXForma TherapeuticsN/AN/AN/AN/AIMVTImmunovant3.00Buy$47.8847.22% UpsideKRYSKrystal Biotech3.00Buy$157.67-11.02% DownsideOCGNOcugen3.00Buy$4.33143.45% UpsideRGNXREGENXBIO2.83Moderate Buy$38.0071.33% UpsideCurrent Analyst RatingsLatest KRYS, RGNX, OCGN, IMVT, and FMTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024IMVTImmunovantOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$50.003/25/2024IMVTImmunovantTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$48.003/13/2024IMVTImmunovantThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$50.003/11/2024RGNXREGENXBIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$36.003/8/2024RGNXREGENXBIORoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSector Perform ➝ Outperform$20.00 ➝ $35.003/7/2024RGNXREGENXBIOChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$52.003/7/2024RGNXREGENXBIOBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$45.00 ➝ $55.003/6/2024RGNXREGENXBIOLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform3/6/2024RGNXREGENXBIOSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$37.003/6/2024RGNXREGENXBIORobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$34.00 ➝ $39.002/28/2024RGNXREGENXBIOWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$21.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFMTXForma Therapeutics$100.56M9.52N/AN/A$10.51 per share1.90IMVTImmunovantN/AN/AN/AN/A$2.78 per shareN/AKRYSKrystal Biotech$50.70M98.88N/AN/A$27.60 per share6.42OCGNOcugenN/AN/AN/AN/A$0.38 per shareN/ARGNXREGENXBIO$90.24M10.92N/AN/A$7.09 per share3.13Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFMTXForma Therapeutics-$172.96M-$4.00N/AN/AN/AN/A-39.68%-35.33%N/AIMVTImmunovant-$210.96M-$1.84N/AN/AN/AN/A-57.97%-52.47%5/27/2024 (Estimated)KRYSKrystal Biotech$10.93M$0.082,215.2848.02N/AN/A-13.31%-12.61%5/13/2024 (Estimated)OCGNOcugen-$81.35M-$0.33N/AN/AN/AN/A-104.70%-81.96%4/2/2024 (Estimated)RGNXREGENXBIO-$263.49M-$6.03N/AN/AN/A-291.99%-68.18%-39.95%5/1/2024 (Estimated)Latest KRYS, RGNX, OCGN, IMVT, and FMTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/27/2024Q4 2023RGNXREGENXBIO-$1.27-$1.43-$0.16-$1.43$34.01 million$22.30 million 2/26/202412/31/2023KRYSKrystal Biotech-$0.52$0.30+$0.82$0.30$27.43 million$42.14 million 2/12/202412/31/2023IMVTImmunovant-$0.43-$0.36+$0.07-$0.36N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFMTXForma TherapeuticsN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFMTXForma TherapeuticsN/A12.7412.74IMVTImmunovantN/A22.1422.14KRYSKrystal BiotechN/A17.7617.55OCGNOcugen0.035.085.08RGNXREGENXBION/A2.572.57OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFMTXForma Therapeutics87.39%IMVTImmunovant47.08%KRYSKrystal Biotech86.29%OCGNOcugen10.27%RGNXREGENXBIO88.08%Insider OwnershipCompanyInsider OwnershipFMTXForma Therapeutics5.79%IMVTImmunovant4.80%KRYSKrystal Biotech17.00%OCGNOcugen3.48%RGNXREGENXBIO12.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableFMTXForma Therapeutics16647.85 million45.08 millionNot OptionableIMVTImmunovant164145.29 million138.32 millionOptionableKRYSKrystal Biotech22928.29 million23.48 millionOptionableOCGNOcugen84256.50 million247.58 millionOptionableRGNXREGENXBIO34444.43 million38.79 millionOptionableKRYS, RGNX, OCGN, IMVT, and FMTX HeadlinesSourceHeadlineREGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMDprnewswire.com - March 28 at 7:05 AMREGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Daysfinance.yahoo.com - March 27 at 5:33 PMREGENXBIO (NASDAQ:RGNX) Upgraded to Hold at StockNews.comamericanbankingnews.com - March 21 at 2:20 AMREGENXBIO (NASDAQ:RGNX) Raised to Hold at StockNews.commarketbeat.com - March 21 at 2:20 AMREGENXBIO Inc. (NASDAQ:RGNX) CEO Kenneth T. Mills Sells 15,000 Sharesamericanbankingnews.com - March 19 at 5:02 AMREGENXBIO Inc. (NASDAQ:RGNX) CEO Sells $327,900.00 in Stockinsidertrades.com - March 19 at 5:00 AMRegenxbio Inc (RGNX) President and CEO Kenneth Mills Sells 15,000 Sharesfinance.yahoo.com - March 18 at 9:18 PMREGENXBIO Inc. (NASDAQ:RGNX) Insider Steve Pakola Sells 12,878 Sharesinsidertrades.com - March 17 at 7:41 AMChardan Capital Comments on REGENXBIO Inc.'s FY2024 Earnings (NASDAQ:RGNX)marketbeat.com - March 14 at 6:57 AMRockville biotech raises $140M following layoffs, program cutsbizjournals.com - March 12 at 8:13 PMREGENXBIO (NASDAQ:RGNX) Upgraded at StockNews.commarketbeat.com - March 11 at 11:15 PMRegenxbio: DMD Program Lends Additional Credibility To NAV Technology Platformseekingalpha.com - March 11 at 2:02 PMRegenxbio initiated with bullish view at H.C. Wainwright, here's whyrealmoney.thestreet.com - March 11 at 2:02 PMHC Wainwright Initiates Coverage on REGENXBIO (NASDAQ:RGNX)marketbeat.com - March 11 at 10:23 AMREGENXBIO to Participate in Upcoming Investor Conferencesprnewswire.com - March 11 at 7:05 AMLeerink Partnrs Equities Analysts Boost Earnings Estimates for REGENXBIO Inc. (NASDAQ:RGNX)marketbeat.com - March 11 at 1:45 AMRBC Capital gets more bullish on Regenxbio, upgrades sharesrealmoney.thestreet.com - March 8 at 2:22 PMRBC Capital upgrades Regenxbio to Outperform, sees positive risk-rewardrealmoney.thestreet.com - March 8 at 2:22 PMRegenxbio raised to Buy at RBC on pivot to Duchennemsn.com - March 8 at 2:22 PMThis Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIOmarkets.businessinsider.com - March 8 at 2:22 PMRegenxbio Inc (RGNX) Chief Medical Officer Steve Pakola Sells 12,878 Sharesfinance.yahoo.com - March 8 at 8:38 AMREGENXBIO (NASDAQ:RGNX) Raised to Outperform at Royal Bank of Canadamarketbeat.com - March 8 at 8:21 AMREGENXBIO Inc. (NASDAQ:RGNX) Expected to Earn Q1 2024 Earnings of ($1.24) Per Sharemarketbeat.com - March 8 at 6:19 AMBearish: Analysts Just Cut Their REGENXBIO Inc. (NASDAQ:RGNX) Revenue and EPS estimatesfinance.yahoo.com - March 7 at 3:33 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsForma TherapeuticsNASDAQ:FMTXForma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.ImmunovantNASDAQ:IMVTImmunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Krystal BiotechNASDAQ:KRYSKrystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.OcugenNASDAQ:OCGNOcugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.REGENXBIONASDAQ:RGNXREGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.